Background: The age-pigment, lipofuscin that accumulates in cells intrinsically and progressively with age is considered as the hallmark of aging. This accumulation is more prominent in post-mitotic cells like neurons and also appears in glia. Purpose: The aim of the present study was to assess the age-associated occurrence and distribution pattern of lipofuscin both in neurons and microglia in various regions of hippocampus and striate cortex. Methods: The accumulation pattern of lipofuscin in hippocampus and striate cortex was observed in the female Wistar rats of 6 age groups, that is, 3, 6, 12, 18, 24, and 30 months using the autofluorescent property of lipofuscin and its specific localization in neurons and microglia by dual immunolabeling with NeuN and Iba-1 antibodies respectively. Cytoarchitectural and the morphological age-related changes were observed with cresyl violet staining. Results: Lipofuscin pigments accumulate progressively through the normal aging process in hippocampus and striate cortex. However, in hippocampus, lipofuscin accumulates in a region-specific manner with the highest accumulation observed in cornu ammonis (CA) 1 and 3 subregions. Furthermore, the lipofuscin accumulation was also observed in microglia in the senile brains both in the hippocampus and striate cortex. Conclusion: The progressive deposition of lipofuscin could result in cellular dysfunction. This encouraged us to forward the idea that microglia not only participate in the removal of the pigment from the neurons but also accumulate these waste products in itself. Such senescent microglia may contribute to age- related neurodegeneration as they lose the neuroprotective potential due to oxidative stress and thus may be unable to effectively phagocytose the age pigment.

Keywords:
Lipofuscin, Hippocampus, Aging, Striate cortex, Microglia
1.
Patro IK, Sharma SP, Patro N: Neuronal lipofuscin: Its formation and reversibility. Ind Rev Life Sci 1988; 8: 95–120.
2.
Patro N, Gupta P, Patro IK: Lipofuscin in cell aging and cell death. Indian J Gerontol 2002; 16: 45–68.
3.
Harman D: Lipofuscin and ceroid formation: the cellular recycling system. Adv Exp Med Biol 1989; 266: 3–15.
4.
Ames BN, Shigenaga MK, Hagen TM: Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 1993; 90: 7951–7922.
5.
Beckman KB, Ames BN: The free radical theory of aging matures. Physiol Rev 1998; 78: 547–581.
6.
Porta EA: Pigments in aging: an overview. Ann N Y Acad Sci 2002; 959: 57–65.
7.
Jolly RD, Douglas BV, Davey PM, Roiri JE: Lipofuscin in bovine muscle and brain: a model for studying age pigment. Gerontology 1995; 41: 283–295.
8.
Jolly RD, Palmer DN, Dalefield RR: The analytical approach to the nature of lipofuscin (age pigment). Arch Gerontol Geriatr 2002; 34: 205–217.
9.
Terman A, Brunk UT: Molecules in focus Lipofuscin. Int J Biochem Cell Biol 2004; 36: 1400–1404.
10.
Kikugawa K, Kato T, Beppu M, Hayasaka A: Fluorescent and cross-linked proteins formed by free radical and aldehyde species generated during lipid oxidation. Adv Exp Med Biol 1989; 266: 345–357.
11.
Double KL, Dedov VN, Fedorow H, Kettle E, Halliday GM, Garner B, Brunk UT: The comparative biology of neuromelanin and lipofuscin in the human brain. Cell Mol Life Sci 2008; 10: 7581–7589.
12.
Terman A, Dalen H, Brunk UT: Ceroid/lipofuscin-loaded human fibroblasts show decreased survival time and diminished autophagocytosis during amino acid starvation. Exp Gerontol 1999; 34: 943–957.
13.
Patro IK, Sharma SP, Patro N: Pre-lipofuscin: the concept and influence of centrophenoxine. Proc Nat Acad Sci (India) 1987; 57: 105–106.
14.
Gilissen EP, Staneva-Dobrovski L: Distinct types of lipofuscin pigment in the hippocampus and cerebellum of aged cheirogaleid primates. Anat Rec 2013; 296: 1895–1906.
15.
Nakano M, Oenzil F, Mizuno T, Gotoh S: Age-related changes in the lipofuscin accumulation of brain and heart. Gerentology 1995; 41: 69–79.
16.
Brizzee KR, Ordy JM, Kaack B: Early appearance and regional differences in intraneuronal and extraneuronal lipofuscin accumulation with age in the brain of a nonhuman primate (Macaca mulatta). J Gerontol 1974; 29: 366–381.
17.
Oenzil F, Kishikawa M, Mizuno T, Nakano M: Age-related accumulation of lipofuscin in three different regions of rat brain. Mech Age Dev 1994; 76: 157–163.
18.
Gerrits PO, Kortekaas R, de Weerd H, Veening JG, van der Want JJ: Regional differences in age-related lipofuscin accumulation in the female hamster brainstem. Neurobiol Aging 2012; 33: 625. e1–e9.
19.
Sohal RS, Brunk UT: Lipofuscin as an indicator of oxidative stress and aging. Adv Exp Med Biol 1989; 266: 17–26.
20.
Goyal VK: Lipofuscin pigment accumulation in human brain during aging. Exp Gerontol 1982; 17: 481–487.
21.
Patro N, Sharma SP, Patro IK: Lipofuscin accumulation in ageing myocardium and its removal by meclophenoxate. Ind J Med Res 1992; 96: 192–198.
22.
Terman A, Brunk UT: Oxidative stress, accumulation of biological “garbage” and aging. Antioxid Redox Signal 2006; 8: 197–204.
23.
Zivkovic V, Stefanovic N, Durovic-Filipovic T, Pavlovic S, Stojanovic V, Bakic M, Kundalic B, Pavlovic M: Patterns of lipofuscin accumulation in ganglionic nerve cells of superior cervical ganglion in humans. Vojnosanit Pregl 2008; 65: 738–742.
24.
Hasan M, Glees P, Spoerri PE: Dissolution and removal of neuronal lipofuscin following dimethyl-aminoethyl p-cholorophenoxyacetate administration to guinea pigs. Cell Tiss Res 1974; 150: 369–375.
25.
Benavides SH, Monserrat AJ, Farina S, Porta EA: Sequential histochemical studies of neuronal lipofuscin in human cerebral cortex from the first to the ninth decade of life. Arch Gerrontol Geriatr 2002; 34: 219–231.
26.
Fonseca DB, Sheehy MR, Blackman N, Shelton PM, Prior AE: Reversal of a hallmark of brain ageing: lipofuscin accumulation. Neurobiol Aging 2004; 26: 69–76.
27.
Riga D, Riga S, Halalau F, Schneider F: Brain lipopigment accumulation in normal and pathological aging. Ann N Y Acad Sci 2006; 1067: 158–163.
28.
Sharma SP, Manocha SL: Lipofuscin formation in the developing nervous system of squirrel monkeys consequent to maternal dietary protein deficiency during gestation. Mech Age Dev 1977; 6: 1–14.
29.
Braak H, Braak E, Gullotta F, Goebel HH: Pigment-filled appendages of the small spiny neurons: a severe pathological change of the striatum in neuronal ceroid lipofuscinosis. Neuropathol Appl Neurobiol 1979; 5: 389–394.
30.
Braak H, Braak E: Neuronal types in the striatum of man. Cell tissue Res 1982; 227: 319–342.
31.
Tigges J, Herndon JG, Peters A: Neuronal population of area 4 during the life span of the rhesus monkey. Neurobiol Aging 1990; 11: 201–208.
32.
Xu H, Chen M, Manivannan A, Lois N, Forrester JV: Age-dependent accumulation of lipofuscin in perivascular and subretinal microglia in experimental mice. Ageing Cell 2008; 7: 58–68.
33.
Glees P, Hasan M: Intracytoplasmic location of lipofuscin granules. In: Lipofuscin in Neuronal Ageing and Disease; in Bergmann W, Doerr W (eds): Advances in Anatomy and Pathology, Georg Thieme Verlag, Stuttgart, 1976, vol 32, pp 10–17.
34.
Brunk UT, Terman A: The mitochondrial-lysosomal axis theory of aging: accumulation of damaged mitochondria as a result of imperfect autophagocytosis. Eur J Biochem 2002; 269: 1996–2002.
35.
Elleder M, Sokolová J, Hrebícek M: Follow-up study of subunit c of mitochondrial ATP synthase (SCMAS) in Batten disease and in unrelated lysosomal disorders. Acta Neuropathol 1997; 4: 374–90.
36.
Koniga J, Ott C, Hugo M, Jung T, Bulteau AL, Grune T, Hohn A: Mitochondrial contribution to lipofuscin formation. Redox Biol 2017; 11: 673–681.
37.
Mann DM, Yates PO: Lipoprotein pigments – their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain 1974; 97, 489–498.
38.
Mann DMA, Yates PO: Ageing, nucleic acids and pigments; in Smith W, Thomas, Cavanagh JB (eds): Recent Advances in Neuropathology. Edinburgh, Churchill Livingstone, 1982, vol 2, pp 109–138.
39.
Brody H: The deposition of aging pigment in the human cerebral cortex. J Gerontol 1960; 15: 258–261.
40.
Braak H: On the striate area of the human isocortex. A Golgi- and pigmetarchitectonic study. J comp Neurol 1976; 166: 341–364.
41.
Peters A, Sethares C: Aging and the Meynert cells in rhesus monkey primary visual cortex. Anal Rec 1993; 236: 721–729.
42.
Humason GL: Animal Tissue Techniques; in Beadle GW, Emerson R, Whitaker DW (eds): W H Freeman and company, San Francisco and London, 1962, pp 195–196.
43.
Miller DB, O’Callaghan JP: Aging, stress and the hippocampus. Ageing Res Rev 2005; 4: 123–140.
44.
Bartsch T, Wulff P: The hippocampus in aging and disease: from plasticity to vulnerability. Neuroscience 2015; 309: 1–16.
45.
Asuncao M, Santos-Marques MJ, Carvalho F, Lukoyanov NV, Andrade JP: Chronic green tea consumption prevent age-related changes in rat hippocampal formation. Neurobiol Aging 2011; 32: 707–717.
46.
Kadar T, Silbermann M, Brandeis R, Levy A: Age-related structural changes in the rat hippocampus: correlation with working memory deficiency. Brain Res 1990; 512: 113–120.
47.
West MJ, Coleman PD, Flood DG, Troncoso JC: Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer’s disease. Lancet 1994; 344: 769–772.
48.
Lucassen PJ, Heine VM, Muller MB, Van der Beek EM, Wiegant VM, De Kloet ER, Joels M, Fuchs E, Swaab DF, Czeh B: Stress, depression and hippocampal apoptosis. CNS Neurol Disord Dru Targets 2006; 5: 531–546.
49.
Padurariu M, Ciobica A, Mavroudis I, Fotiou D, Baloyannis S: Hippocampal neuronal loss in the CA1 and CA3 areas of Alzheimer’s disease patients. Psychiatria Danubina 2012; 24: 152–158.
50.
Zhao X, Lein ES, He A, Smith SC, Aston C, Gage FH: Transcriptional profiling reveals strict boundaries between hippocampal subregions. J Comp Neurol 2001; 441: 187–196.
51.
Thompson CL, Pathak SD, Jeromin A, Ng LL, MacPherson CR, Mortrud MT, Cusick A, Riley ZL, Sunkin SM, Bernard A, Puchalski RB, Gage FH, Jones AR, Bajic VB, Hawrylycz MJ, Lein ES: Genomic anatomy of the hippocampus. Neuron 2008; 60: 1010–1021.
52.
Fanselow MS, Dong HW: Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 2010; 65: 7–19.
53.
Riew TR, Kim HL, Choi JH, Jin X, Shin YJ, Lee MY: Progressive accumulation of autofluorescent granules in macrophages in rat striatum after systemic 3-nitropropionic acid: a correlative light- and electron-microscopic study. Histochem Cell Biol 2017; 148: 517–528.
54.
Vida C, de Toda IM, Cruces J, Garrido A, Gonzalez-Sanchez M, De La Fuente M: Role of macrophages in age-related oxidative stress and lipofuscin accumulation in mice. Redox Biol 2017; 12: 423–437.
55.
Brunk UT, Terman A: Lipofuscin: Mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med 2002; 33: 611–619.
56.
Mestre N, Bons N: Age-related cytological changes and neuronal loss in basal forebrain cholinergic neurons in Microcebus murinus (lemurian, primate). Neurodegeneration 1993; 2: 25–32.
57.
Dorey CK, Wu G, Ebenstein D, Garsd A, Weiter JJ: Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. Invest Ophthalmol Vis Sci 1989; 30: 1691–1699.
58.
Dowson JH, Mountjoy CQ, Cairns MR, Wilton-Cox H: Changes in intraneuronal lipopigment in Alzheimer’s disease. Neurobiol Aging 1992; 13: 493–500.
59.
Wolf G: Lipofuscin and macular degeneration. Nutr Rev 2003; 61: 342–346.
60.
Sparrow JR, Boulton M: RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 2005; 80: 595–606.
61.
Liu JY, Reeves C, Diehl B, Coppola A, Al-Hajri A, Hoskote C, Mughairy SA, Tachrount M, Groves M, Michalak Z, Mills K, McEvoy AW, Miserocchi A, Sisodiya SM, Thom M: Early lipofuscin accumulation in frontal lobe epilepsy. Ann Neurol 2016; 80: 882–895.
62.
Anderson OA, Finkelstein A, Shima DT: A2E induces IL-1ß production in retinal pigment epithelial cells via the NLRP3 Inflammasome. PLoS One 2013; 8:e67263.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.